Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in eosinophilic asthma
NL-OMON36320Phase 3Active, not recruiting
- Sponsor
- Cephalon, Inc.
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of reslizumab in eosinophilic asthma (EA) (3 arms), sponsored by Cephalon, Inc. Primary endpoint: Change from baseline in FEV1. Started Nov 2011; status: active, not recruiting.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON36320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36320.